Sharp Therapeutics Corp.
SHRX.V
TSX
| 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | 06/30/2023 | |
|---|---|---|---|---|---|
| Net Income | -4.91M | -4.24M | -3.56M | -- | -- |
| Total Depreciation and Amortization | 103.00K | 108.70K | 114.40K | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 2.05M | 1.69M | 1.33M | -- | -- |
| Change in Net Operating Assets | 581.20K | 370.30K | 159.40K | -- | -- |
| Cash from Operations | -2.18M | -2.07M | -1.96M | -- | -- |
| Capital Expenditure | -14.40K | -12.40K | -10.40K | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -14.40K | -12.40K | -10.40K | -- | -- |
| Total Debt Issued | -32.20K | -16.10K | 0.00 | -- | -- |
| Total Debt Repaid | -200.00K | -200.00K | -200.00K | -- | -- |
| Issuance of Common Stock | 2.38M | 2.38M | 2.38M | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -29.60K | -14.80K | -- | -- | -- |
| Cash from Financing | 2.12M | 2.15M | 2.18M | -- | -- |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -74.00K | 69.30K | 212.60K | -- | -- |